SCHEMBL12875705

SCHEMBL12875705

Cc1cccc(-c2csc(Cn3cc(C(N)=O)cn3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 2/20 0.46
ATP4B P51164 2/20 0.46
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
DHODH Q02127 1/20 0.40
IRAK4 Q9NWZ3 2/20 0.40
TLR8 Q9NR97 2/20 0.39
KLKB1 P03952 3/20 0.39
SCN9A Q15858 1/20 0.39
CSNK1D P48730 1/20 0.39
CSNK1E P49674 1/20 0.39
MAPK14 Q16539 1/20 0.39
NAMPT P43490 1/20 0.39
FYN P06241 1/20 0.39
MEN1 O00255 1/20 0.39
C1S P09871 1/20 0.38
AKT1 P31749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875682 0.91 SIRT5 (0.44) ATP4AATP4BALDH1A1RAB9AL3MBTL1
SCHEMBL12875680 0.87 L3MBTL1 (0.44) ATP4AATP4BALDH1A1L3MBTL1PDE3B
SCHEMBL1198894 0.85 ALDH1A1 (0.51) ALDH1A1MEN1
SCHEMBL27827176 0.81 TSHR (0.44) ALDH1A1RAB9AL3MBTL1KLKB1MEN1
SCHEMBL1198716 0.80 SMN1; SMN2 (0.46) ALDH1A1RAB9AL3MBTL1CSNK1DMEN1
SCHEMBL1198883 0.80 EIF4E (0.46) ALDH1A1RAB9AL3MBTL1KLKB1FYN
SCHEMBL1199302 0.80 HDAC3 (0.44) ALDH1A1RAB9AL3MBTL1KLKB1MEN1
SCHEMBL12875706 0.79 CYP11B1 (0.43) ATP4AATP4BPDE3BPDE3AIRAK4
SCHEMBL13650678 0.78 L3MBTL1 (0.43) ALDH1A1L3MBTL1IRAK4MEN1AKT1
SCHEMBL1198553 0.78 ALDH1A1 (0.44) ALDH1A1RAB9AL3MBTL1MEN1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ATP4A 2758/4885ATP4B 2711/4885ALDH1A1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.